Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Delphys plus is a combination dietary supplement developed by Farmares Srl for the management of uterine fibroids (leiomyomas). The product contains a synergistic blend of 150 mg epigallocatechin gallate (EGCG), 1,000 IU vitamin D3, 5 mg vitamin B6, and 25–50 mg D-chiro-inositol. Its mechanism of action involves the modulation of the VEGF receptor signaling pathway and the reduction of cellular proliferation markers, including ki67, estrogen receptors (ER), and progesterone receptors (PR). Clinical evidence suggests that the supplement effectively reduces fibroid volume and alleviates symptoms such as heavy menstrual bleeding after three months of use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epigallocatechin gallate + vitamin D + D-chiro-inositol + vitamin B6.